Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15488993 | 0.92 | MDM2 (1.00) | MDM2P4HB | |
| SCHEMBL9965537 | 0.86 | MDM2 (0.66) | MDM2P4HB | |
| SCHEMBL12515875 | 0.82 | MDM2 (0.82) | MDM2P4HB | |
| SCHEMBL9965484 | 0.82 | MDM2 (0.67) | MDM2P4HB | |
| SCHEMBL9965729 | 0.81 | MDM2 (0.72) | MDM2P4HB | |
| SCHEMBL9965761 | 0.80 | MDM2 (0.69) | MDM2P4HB | |
| SCHEMBL9965698 | 0.79 | MDM2 (0.63) | MDM2P4HB | |
| SCHEMBL9965720 | 0.79 | MDM2 (0.64) | MDM2P4HB | |
| SCHEMBL9965641 | 0.79 | MDM2 (0.71) | MDM2P4HB | |
| SCHEMBL9965652 | 0.79 | MDM2 (0.67) | MDM2P4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658170-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | Errico, Joseph P. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | TP53, EGFR, MDM2 | MDM2 3/4885P4HB 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.